Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
Want to see AVR full AI Analyst Report?
Top Page
Anteris Technologies Global Corp.
(NASDAQ:AVR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$8.50
▲(49.65% Upside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by very weak fundamentals—shrinking revenue, heavy losses, and severe ongoing cash burn—despite low reported leverage in the latest period. Technical momentum is currently constructive and corporate actions are modestly positive, but valuation metrics provided offer little support.
Positive Factors
Board financial expertise
Adding a veteran finance executive to the board and reinforcing audit oversight strengthens governance and financial discipline. Over 2–6 months this improves capital allocation, audit rigor, and credibility with lenders/investors, reducing execution risk during capital raises or scaling.
Negative Factors
Severe persistent cash burn
Large, ongoing negative cash flows create continuous financing needs and elevate dilution and refinancing risk. Over several months this limits strategic flexibility, forces prioritization of projects, and could constrain commercialization if additional capital is not secured on acceptable terms.
Read all positive and negative factors
Positive Factors
Negative Factors
Board financial expertise
Adding a veteran finance executive to the board and reinforcing audit oversight strengthens governance and financial discipline. Over 2–6 months this improves capital allocation, audit rigor, and credibility with lenders/investors, reducing execution risk during capital raises or scaling.
Read all positive factors
Anteris Technologies Global Corp. (AVR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$839.09M
Dividend YieldN/A
Average Volume (3M)151.40K
Price to Earnings (P/E)―
Beta (1Y)1.93
Revenue Growth-25.74%
EPS Growth2.38%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-4.00
Shares Outstanding97,342,200
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap0.06
Enterprise Value/Revenue27.89
Enterprise Value/Gross Profit98.70
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$16.00Price Target Upside181.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$8.13M
Anteris Technologies Global Corp. Business Overview & Revenue Model
Company Description
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart v...
How the Company Makes Money
null...
Anteris Technologies Global Corp. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.85M | 1.91M | 2.70M | 2.73M | 3.20M | 5.83M |
| Gross Profit | 523.00K | -317.00K | 1.27M | 876.80K | 298.38K | 1.91M |
| EBITDA | -94.36M | -92.23M | -76.86M | -45.54M | -29.14M | -15.50M |
| Net Income | -95.30M | -94.14M | -76.29M | -46.02M | -30.56M | -17.17M |
Balance Sheet | ||||||
| Total Assets | 294.72M | 23.00M | 80.70M | 30.53M | 15.99M | 21.43M |
| Cash, Cash Equivalents and Short-Term Investments | 283.21M | 12.58M | 70.46M | 21.03M | 9.29M | 15.46M |
| Total Debt | 3.73M | 2.28M | 1.40M | 1.60M | 952.79K | 4.14M |
| Total Liabilities | 16.31M | 23.25M | 18.02M | 11.63M | 6.95M | 10.91M |
| Stockholders Equity | 278.44M | -93.00K | 62.76M | 19.30M | 9.03M | 10.52M |
Cash Flow | ||||||
| Free Cash Flow | -86.69M | -79.76M | -63.51M | -37.03M | -31.08M | -15.02M |
| Operating Cash Flow | -84.99M | -77.80M | -61.24M | -34.63M | -29.42M | -14.44M |
| Investing Cash Flow | -1.89M | -596.00K | -2.28M | -2.58M | -992.57K | -886.07K |
| Financing Cash Flow | 321.16M | 20.55M | 112.83M | 49.34M | 23.27M | 27.42M |
Anteris Technologies Global Corp. Technical Analysis
Positive
5.68
Price Trends
6.07
Positive
5.88
Positive
5.16
Positive
Market Momentum
0.52
Negative
82.38
Negative
95.63
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVR, the sentiment is Positive. The current price of 5.68 is below the 20-day moving average (MA) of 6.54, below the 50-day MA of 6.07, and above the 200-day MA of 5.16, indicating a bullish trend. The MACD of 0.52 indicates Negative momentum. The RSI at 82.38 is Negative, neither overbought nor oversold. The STOCH value of 95.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVR.
Anteris Technologies Global Corp. Risk Analysis
Anteris Technologies Global Corp. disclosed 67 risk factors in its most recent earnings report. Anteris Technologies Global Corp. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anteris Technologies Global Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $158.70M | -18.45 | -90.62% | ― | 18.22% | 59.78% | |
52 Neutral | $839.09M | -1.42 | -124.39% | ― | -25.74% | 2.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $201.45M | -9.70 | -7.74% | ― | -15.41% | 79.57% | |
49 Neutral | $171.65M | -5.07 | -12.90% | ― | 3.39% | 19.78% | |
48 Neutral | $182.94M | -1.20 | -69.50% | ― | -1.66% | -12.59% | |
45 Neutral | $91.99M | -1.81 | -131.52% | ― | 15.99% | -8.91% |
* Healthcare Sector Average
AVR
Anteris Technologies Global Corp.
9.00
5.77
178.64%
ANIK
Anika Therapeutics
15.02
3.25
27.61%
APYX
Apyx Medical
4.25
2.59
156.02%
INGN
Inogen
6.41
-0.34
-5.04%
TMCI
Treace Medical Concepts
2.84
-3.26
-53.44%
RPID
Rapid Micro Biosystems
2.07
-1.08
-34.29%
Anteris Technologies Global Corp. Corporate Events
Executive/Board Changes
Anteris Technologies Adds Experienced Financial Leaders to Board
Positive
May 13, 2026
On May 11, 2026 in the U.S. (May 12, 2026 in Australia), Anteris Technologies Global Corp. appointed Susan Knight and returning director Stephen Denaro to its Board of Directors, assigning Knight as a Class I Director through the 2028 annual meeti...
Business Operations and Strategy
Anteris Ends v2vmedtech Development Agreement, Limits Exposure
Neutral
Apr 29, 2026
On April 28, 2026, Anteris Technologies Global Corp., via its subsidiary, elected to discontinue further development contributions under its April 18, 2023 Contribution and Stock Purchase Agreement with v2vmedtech, inc., after completing Stage 1 a...
Business Operations and Strategy
Anteris Technologies Signs Major Brooklyn Park Facility Lease
Positive
Apr 23, 2026
On April 23, 2026, Anteris Technologies Global Corp., via its Anteris Technologies Corporation subsidiary, signed a lease for about 181,436 square feet of office and warehouse space in Brooklyn Park, Minnesota, with an initial term running from Se...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.